VKTX Viking Therapeutics Inc.

Viking Therapeutics Inc.

Biotechnology: Pharmaceutical Preparations

Health Care

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRÃ for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

IPO Year: 2015

Exchange: NASDAQ

Website: vikingtherapeutics.com

Peers

Recent Analyst Ratings for Viking Therapeutics Inc.

Date	Price Target	Rating	Analyst
4/29/2025	$104.00	Overweight	Cantor Fitzgerald
4/8/2025	$30.00	Neutral	Goldman
2/13/2025	$102.00	Sector Outperform	Scotiabank
2/7/2025	$38.00	Neutral	Citigroup
12/2/2024		Overweight	Piper Sandler
11/22/2024	$109.00	Buy	B. Riley Securities
11/4/2024	$90.00 → $102.00	Buy	H.C. Wainwright
9/11/2024	$80.00	Overweight	JP Morgan
6/27/2024	$105.00	Overweight	Morgan Stanley
5/16/2024	$115.00 → $116.00	Outperform → Strong Buy	Raymond James

See more ratings

Viking Therapeutics Inc.

Peers

Recent Analyst Ratings for Viking Therapeutics Inc.

Viking Therapeutics Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Amendment: Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

Viking Therapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Foehr Matthew W exercised 20,786 shares at a strike of $8.00, increasing direct ownership by 19% to 132,036 units (SEC Form 4)

Amendment: Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

President & CEO Lian Brian was granted 256,133 shares and sold $8,313,601 worth of shares (194,490 units at $42.75), increasing direct ownership by 3% to 2,366,570 units (SEC Form 4)

Chief Operating Officer Mancini Marianna was granted 66,200 shares and sold $2,317,599 worth of shares (54,215 units at $42.75), increasing direct ownership by 3% to 374,134 units (SEC Form 4)

Chief Financial Officer Zante Greg sold $2,150,595 worth of shares (50,309 units at $42.75) and was granted 66,200 shares, increasing direct ownership by 11% to 165,259 units (SEC Form 4)

SEC Form 4 filed by Director Macartney Lawson

SEC Form 4 filed by Director Singleton J Matthew

SEC Form 4 filed by Director Rowland Charles A Jr

SEC Form 4 filed by Director Foehr Matthew W